CY1116032T1 - 8-χλωρο-3-πεντυλο-3,7-διυδρο-1η-πουρινο-2,6-διονο-2-αμινο-2-(υδροξυμεθυλο)-1,3-προπανοδιολη ανυδρο αλας για τη θεραπεια ασθενειων - Google Patents

8-χλωρο-3-πεντυλο-3,7-διυδρο-1η-πουρινο-2,6-διονο-2-αμινο-2-(υδροξυμεθυλο)-1,3-προπανοδιολη ανυδρο αλας για τη θεραπεια ασθενειων

Info

Publication number
CY1116032T1
CY1116032T1 CY20141101047T CY141101047T CY1116032T1 CY 1116032 T1 CY1116032 T1 CY 1116032T1 CY 20141101047 T CY20141101047 T CY 20141101047T CY 141101047 T CY141101047 T CY 141101047T CY 1116032 T1 CY1116032 T1 CY 1116032T1
Authority
CY
Cyprus
Prior art keywords
purino
pentyl
chloro
treatment
salt
Prior art date
Application number
CY20141101047T
Other languages
English (en)
Inventor
Holly Esken
Beth Adams Norton
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CY1116032T1 publication Critical patent/CY1116032T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ένα άλας τρις της 8-χλωρο-3-πεντυλο-3,7-διυδρο-1H-πουρινο-2,6-διόνης με τύπο (Α): αντίστοιχες μεθόδους παρασκευής, φαρμακευτικά σκευάσματα που το περιέχουν και χρήσεις της προαναφερθείσας ένωσης στη θεραπεία, ιδιαίτερα στην θεραπεία ασθενειών όπου η υπο-ενεργοποίηση του υποδοχέα ΗΜ74Α συνεισφέρει στην ασθένεια ή όπου η ενεργοποίηση του υποδοχέα θα είναι ευεργετική.
CY20141101047T 2008-12-08 2014-12-16 8-χλωρο-3-πεντυλο-3,7-διυδρο-1η-πουρινο-2,6-διονο-2-αμινο-2-(υδροξυμεθυλο)-1,3-προπανοδιολη ανυδρο αλας για τη θεραπεια ασθενειων CY1116032T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12059608P 2008-12-08 2008-12-08
EP09832421.3A EP2370440B1 (en) 2008-12-08 2009-12-07 8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione 2-amino-2-(hydroxymethyl)-1,3-propanediol anhydrate for the treatment of diseases

Publications (1)

Publication Number Publication Date
CY1116032T1 true CY1116032T1 (el) 2017-01-25

Family

ID=42243044

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141101047T CY1116032T1 (el) 2008-12-08 2014-12-16 8-χλωρο-3-πεντυλο-3,7-διυδρο-1η-πουρινο-2,6-διονο-2-αμινο-2-(υδροξυμεθυλο)-1,3-προπανοδιολη ανυδρο αλας για τη θεραπεια ασθενειων

Country Status (22)

Country Link
US (3) US9163024B2 (el)
EP (1) EP2370440B1 (el)
JP (1) JP5666464B2 (el)
KR (1) KR101743783B1 (el)
CN (1) CN102245606B (el)
AU (1) AU2009324811B2 (el)
BR (1) BRPI0922134A2 (el)
CA (1) CA2746316C (el)
CY (1) CY1116032T1 (el)
DK (1) DK2370440T3 (el)
EA (1) EA020037B1 (el)
ES (1) ES2527354T3 (el)
HR (1) HRP20150026T1 (el)
IL (1) IL213032A (el)
MX (1) MX2011006022A (el)
PL (1) PL2370440T3 (el)
PT (1) PT2370440E (el)
RS (1) RS53777B1 (el)
SI (1) SI2370440T1 (el)
SM (1) SMT201500012B (el)
WO (1) WO2010068581A1 (el)
ZA (1) ZA201103397B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG157242A1 (en) 2004-02-14 2009-12-29 Smithkline Beecham Corp Medicaments with hm74a receptor agonist activity
AR055369A1 (es) 2005-08-10 2007-08-22 Smithkline Beecham Corp Compuestos derivados de xantina, su uso para preparar un medicamento para el tratamiento de una enfermedad mediada por el receptor hm74a, formulaciones y combinacion farmaceuticas que la comprenden y metodo de preparacion de los mismos
KR102158992B1 (ko) * 2012-03-22 2020-09-23 브이티브이 테라퓨틱스 엘엘씨 소-분자 ｇｌｐ1ｒ 아고니스트의 트리스(하이드록시메틸)아미노메탄 염과 그것의 제약 조성물 및 사용

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657327A (en) * 1970-06-01 1972-04-18 Upjohn Co Prostaglandin salts of tris(hydroxymethyl)aminomethane
US4647585A (en) * 1984-11-08 1987-03-03 E. R. Squibb & Sons, Inc. Bicycloheptane substituted ethers
WO2001043692A2 (en) * 1999-12-15 2001-06-21 Smithkline Beecham Corporation SALTS OF Cis-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID
US20030013905A1 (en) 2002-06-10 2003-01-16 Huang Guishu Kris Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid
SG157242A1 (en) 2004-02-14 2009-12-29 Smithkline Beecham Corp Medicaments with hm74a receptor agonist activity
GB0423568D0 (en) * 2004-10-22 2004-11-24 Smithkline Beecham Corp Novel compounds
US20090209561A1 (en) 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
AR055369A1 (es) 2005-08-10 2007-08-22 Smithkline Beecham Corp Compuestos derivados de xantina, su uso para preparar un medicamento para el tratamiento de una enfermedad mediada por el receptor hm74a, formulaciones y combinacion farmaceuticas que la comprenden y metodo de preparacion de los mismos
GB0516464D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds

Also Published As

Publication number Publication date
JP2012511028A (ja) 2012-05-17
AU2009324811A1 (en) 2011-06-23
MX2011006022A (es) 2011-06-28
BRPI0922134A2 (pt) 2015-08-18
PL2370440T3 (pl) 2015-05-29
SI2370440T1 (sl) 2015-02-27
KR101743783B1 (ko) 2017-06-05
SMT201500012B (it) 2015-05-03
EA201170783A1 (ru) 2011-12-30
ES2527354T3 (es) 2015-01-22
EP2370440A1 (en) 2011-10-05
ZA201103397B (en) 2012-01-25
CA2746316A1 (en) 2010-06-17
RS53777B1 (en) 2015-06-30
EP2370440B1 (en) 2014-11-12
US9163024B2 (en) 2015-10-20
CA2746316C (en) 2017-01-03
AU2009324811B2 (en) 2013-01-24
PT2370440E (pt) 2015-01-14
CN102245606B (zh) 2014-08-20
JP5666464B2 (ja) 2015-02-12
US20170027945A1 (en) 2017-02-02
IL213032A0 (en) 2011-07-31
CN102245606A (zh) 2011-11-16
HRP20150026T1 (hr) 2015-02-13
KR20110097816A (ko) 2011-08-31
US20150366870A1 (en) 2015-12-24
US20110251218A1 (en) 2011-10-13
DK2370440T3 (en) 2014-12-08
EP2370440A4 (en) 2012-05-30
WO2010068581A1 (en) 2010-06-17
IL213032A (en) 2015-02-26
EA020037B1 (ru) 2014-08-29

Similar Documents

Publication Publication Date Title
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1126044T1 (el) Πυραζολο[1,5-αλφα]πυριμιδινες χρησιμες ως αναστολεις της κινασης atr για την αντιμετωπιση καρκινικων νοσων
CY1120778T1 (el) Αναστολεις αντιγραφης ιων γριπης
CY1119056T1 (el) Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
CY1119880T1 (el) Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
CY1119971T1 (el) Αναστολεις gsk-3
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
CY1111903T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
CY1117595T1 (el) Πυραζολο-κιναζολινες ως ρυθμιστες δραστικοτητας της πρωτεϊνικης κινασης
CY1117996T1 (el) Genz 112638 για την θεραπευτικη αγωγη της νοσου gaucher ή fabry σε θεραπεια συνδυασμου
CY1115738T1 (el) Κρυσταλλικα επιδιαλυτωμενα συμπλοκα των παραγωγων (1s)-1,5-anyδpo-1-c-(3-((φainyλ)meθυλ) φαινυλ)-d-γλουσιτολης με αλκοολες οπως αναστολεις sglt2 για τη θεραπευτικη αντιμετωπιση του διαβητη
CY1116929T1 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β
CY1117962T1 (el) Υδροχλωρικο αλας 4-[2-[[5-μεθυλο-1-(2- ναφθαλενυλο)-1η- πυραζολ-3-υλ]οξυ]αιθυλο] μορφολινης
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
CY1113024T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων
CY1111702T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
CY1105962T1 (el) Υποκατεστημενα παραγωγα διοξειδιου θειαζολο-βενζοϊσοθειαζολιου, μεθοδος για την παραγωγη αυτων και η χρηση αυτων
CY1111203T1 (el) 4-ανιλινοκινολινο-3-καρβοξαμιδια ως αναστολεις κινασης csf-1r
CY1122182T1 (el) Ανοσοκατασταλτικες φαρμακοτεχνικες μορφες
EA201170983A1 (ru) Производные тиадиазолов и оксадиазолов, их получение и их применение в терапии
CY1116802T1 (el) Ετεροκυκλικες ενωσεις
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments